393 related articles for article (PubMed ID: 33730652)
21. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Zammarrelli WA; Ma W; Espino K; Gordhandas S; Yeoshoua E; Ehmann S; Zhou Q; Iasonos A; Abu-Rustum NR; Aghajanian C; Green AK; Rubinstein MM; Makker V
Gynecol Oncol; 2023 Nov; 178():27-35. PubMed ID: 37748268
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab.
Aratani S; Sugano T; Shimizu A; Seike M; Kashiwagi T; Gemma A; Sakai Y
CEN Case Rep; 2022 Feb; 11(1):97-104. PubMed ID: 34406602
[TBL] [Abstract][Full Text] [Related]
23. Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.
Choi S; Seo S; Lee JH; Suh KJ; Kim JW; Kim JW; Kim SH; Kim YJ; Lee KW; Kim JH; Kim TW; Hong YS; Kim SY; Kim JE; Kim SW; Lee DH; Lee JC; Choi CM; Yoon S; Koh SJ; Min YJ; Ahn Y; Kim HJ; Baek JH; Park SR; Kim JH
Cancer Res Treat; 2024 Apr; 56(2):404-413. PubMed ID: 37933112
[TBL] [Abstract][Full Text] [Related]
24. Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI; Yoshida T; Yagishita S; Ohuchi M; Sakiyama N; Torasawa M; Shirasawa M; Masuda K; Shinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Hamada A; Ohe Y
J Thorac Oncol; 2022 Oct; 17(10):1227-1232. PubMed ID: 35788404
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance.
Kanbayashi Y; Kobayashi M; Anzai M; Shimizu T; Uchida M
Oncology; 2023; 101(12):817-821. PubMed ID: 37591211
[TBL] [Abstract][Full Text] [Related]
26. Safety outcomes of pembrolizumab with platinum agent chemotherapy combined with 5-fluorouracil or taxane derivative in head and neck cancer.
Lee B; Chehab SS; Fan W; Schell MJ; Kirtane KS; Shah AB
J Oncol Pharm Pract; 2023 Dec; ():10781552231217686. PubMed ID: 38043938
[TBL] [Abstract][Full Text] [Related]
27. Positivity of the KEYNOTE-394 but negativity of the KEYNOTE-240: differences in efficacy between Eastern and Western populations?
Bourien H; Edeline J
Chin Clin Oncol; 2023 Aug; 12(4):34. PubMed ID: 37574572
[No Abstract] [Full Text] [Related]
28. Positive rechallenge of hemophagocytic lymphohistiocytosis in a patient treated with isoniazide, pembrolizumab, carboplatine and pemetrexed.
Bertin B; Auffret M; Chabert P
Therapie; 2023; 78(6):762-764. PubMed ID: 36682965
[No Abstract] [Full Text] [Related]
29. Folinic Acid to Prevent Pemetrexed-Associated Neutropenia After Intrathecal Administration: A Quick Win.
Contrucci RR; Ter Heine R; Hendriks LEL; de Rouw N
J Thorac Oncol; 2023 Aug; 18(8):e81-e82. PubMed ID: 37479332
[No Abstract] [Full Text] [Related]
30. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database.
Naganuma M; Motooka Y; Sasaoka S; Hatahira H; Hasegawa S; Fukuda A; Nakao S; Shimada K; Hirade K; Mori T; Yoshimura T; Kato T; Nakamura M
SAGE Open Med; 2018; 6():2050312118772475. PubMed ID: 29770217
[TBL] [Abstract][Full Text] [Related]
31. Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study.
Gómez-Randulfe I; Califano R
Transl Lung Cancer Res; 2023 Aug; 12(8):1812-1815. PubMed ID: 37691870
[No Abstract] [Full Text] [Related]
32. Edema of the face and extremities secondary to pemetrexed.
Doyle T; Fay CJ; Pisano C; LeBoeuf NR
JAAD Case Rep; 2023 Aug; 38():20-22. PubMed ID: 37600745
[No Abstract] [Full Text] [Related]
33. Methodologic Concerns in Secondary Analysis of KEYNOTE-048-Reply.
Yu Y; Sherman EJ; Lee NY
JAMA Oncol; 2022 Dec; 8(12):1854-1855. PubMed ID: 36264562
[No Abstract] [Full Text] [Related]
34. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Rodríguez-Abreu D; Powell SF; Hochmair MJ; Gadgeel S; Esteban E; Felip E; Speranza G; De Angelis F; Dómine M; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Kurata T; Yang J; Pietanza MC; Souza F; Garassino MC
Ann Oncol; 2021 Jul; 32(7):881-895. PubMed ID: 33894335
[TBL] [Abstract][Full Text] [Related]
36. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leal TA; Riess JW; Jensen E; Zhao B; Pietanza MC; Brahmer JR
J Clin Oncol; 2021 Jul; 39(21):2339-2349. PubMed ID: 33872070
[TBL] [Abstract][Full Text] [Related]
37. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
38. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
39. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Majem M; Cobo M; Isla D; Marquez-Medina D; Rodriguez-Abreu D; Casal-Rubio J; Bueno TM; Bernabé-Caro R; Parente DP; Ruiz-Gracia P; Arroyo MM; Paz-Ares L
J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33810441
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J; Fuchs CS; Shitara K; Tabernero J; Muro K; Van Cutsem E; Bang YJ; De Vita F; Landers G; Yen CJ; Chau I; Elme A; Lee J; Özgüroglu M; Catenacci D; Yoon HH; Chen E; Adelberg D; Shih CS; Shah S; Bhagia P; Wainberg ZA
JAMA Oncol; 2021 Jun; 7(6):895-902. PubMed ID: 33792646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
